GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZXF) » Definitions » Notes Receivable

SDZXF (Sandoz Group AG) Notes Receivable : $0 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Notes Receivable?

Sandoz Group AG's Notes Receivable for the quarter that ended in Jun. 2024 was $0 Mil.


Sandoz Group AG Notes Receivable Historical Data

The historical data trend for Sandoz Group AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Notes Receivable Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Notes Receivable
- -

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Notes Receivable - - - -

Sandoz Group AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Sandoz Group AG Notes Receivable Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG Business Description

Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines